Breaking News Instant updates and real-time market news.

GSK

GlaxoSmithKline

$42.34

0.3 (0.71%)

15:38
09/29/19
09/29
15:38
09/29/19
15:38

GlaxoSmithKline announces results from PRIMA

GlaxoSmithKline announced results from PRIMA, the Phase 3 randomised, double-blind, placebo-controlled study of Zejula as a maintenance therapy in women with first-line ovarian cancer following a response to platinum-based chemotherapy. Niraparib treatment resulted in a 38% reduction in the risk of disease progression or death in the overall population. These results were driven by a clinically meaningful reduction in risk of progression in women with: BRCA mutation tumours; HR-deficient BRCA wild type tumours; HR-proficient tumours. The PRIMA study enrolled patients with a response to their first-line treatment with platinum-based chemotherapy including those with high risk of disease progression, a population with high unmet need and previously under-represented in first-line ovarian cancer studies. In an interim analysis of overall survival, niraparib also demonstrated an encouraging trend toward improvement in OS relative to placebo. A pre-planned interim analysis of OS numerically favoured niraparib in the overall population. In the HR-deficient subgroup, 91% of women on niraparib were alive at 24 months vs. 85% for placebo. These data are not yet mature, and the significance is not fully known. The OS interim analysis also showed 81% of women receiving niraparib in the HR-proficient subgroup were alive at 24 months vs. 59% of women receiving placebo. Niraparib is not currently approved in the first-line ovarian cancer maintenance setting. GSK will share these data with the relevant health authorities and is on track to file by the end of the year. The safety profile demonstrated in PRIMA did not differ from the established safety profile. Validated patient reported outcomes indicate quality of life was similar between the niraparib and placebo treatment arms. Niraparib is marketed in the United States and Europe under the trade name Zejula.

  • 02

    Oct

GSK GlaxoSmithKline
$42.34

0.3 (0.71%)

08/13/19
JPMS
08/13/19
INITIATION
JPMS
Neutral
GlaxoSmithKline reinstated with a Neutral at JPMorgan
JPMorgan analyst James Gordon reinstated coverage of GlaxoSmithKline with a Neutral rating and 1,700p price target. The analyst sees the stock near-term being Brexit and currency moves.
09/03/19
SOCG
09/03/19
UPGRADE
SOCG
Buy
GlaxoSmithKline upgraded to Buy from Sell at Societe Generale
09/03/19
SOCG
09/03/19
UPGRADE
SOCG
Buy
Societe Generale double upgrades GlaxoSmithKline to Buy
As previously reported, Societe Generale analyst Justin Smith upgraded GlaxoSmithKline to Buy from Sell in a research note titled 'An intriguing metamorphosis.' The analyst said he waited to upgrade the stock, despite liking "all the management and capital allocation changes" that new CEO Emma Walmsley has made in her first two years in charge, because he wanted to see "clear evidence of improving innovation" with GlaxoSmithKline's Pharma business. Smith now sees five high profile assets in Phase 3 that will release results in the next 3-4 years, giving improved pipeline visibility, and leaving the analyst forecasting "above-average sales growth from 2023."
09/04/19
COWN
09/04/19
NO CHANGE
Target $48
COWN
Outperform
Pfizer shares remain attractively valued, says Cowen
Cowen analyst Steve Scalia updated his Pfizer (PFE) model following Q2 results, the closing of the Glaxo (GSK) Consumer joint venture, and the announcement that its Upjohn business would be divested and combined with Mylan (MYL). The analyst lowered his estimates to reflect what is left at the company and despite his revision feels the shares remain attractively valued. Scalia reiterated his Outperform rating and $48 price target on Pfizer shares.

TODAY'S FREE FLY STORIES

AKAM

Akamai

$91.36

1.48 (1.65%)

11:51
10/15/19
10/15
11:51
10/15/19
11:51
Hot Stocks
Akamai announces 'enhancements,' new features for Edge Platform »

Akamai Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Oct

  • 05

    Nov

  • 06

    Nov

  • 19

    Nov

GD

General Dynamics

$179.33

0.16 (0.09%)

11:47
10/15/19
10/15
11:47
10/15/19
11:47
Hot Stocks
General Dynamics' Gulfstream G500 earns European certification »

General Dynamics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 12

    Nov

11:47
10/15/19
10/15
11:47
10/15/19
11:47
Conference/Events
Wolfe Research tech strategist to hold a webcast »

Tech Strategist…

QCOM

Qualcomm

$77.55

1.26 (1.65%)

, MSFT

Microsoft

$141.46

1.92 (1.38%)

11:46
10/15/19
10/15
11:46
10/15/19
11:46
Hot Stocks
Qualcomm developing chip preconfigured with the Azure Sphere for IoT »

Qualcomm (QCOM)…

QCOM

Qualcomm

$77.55

1.26 (1.65%)

MSFT

Microsoft

$141.46

1.92 (1.38%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 26

    Oct

  • 27

    Oct

  • 29

    Oct

  • 06

    Nov

  • 06

    Nov

  • 21

    Nov

BC

Brunswick

$54.42

0.715 (1.33%)

11:45
10/15/19
10/15
11:45
10/15/19
11:45
Hot Stocks
Brunswick boosts quarterly dividend 14% »

The board of Brunswick…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

11:37
10/15/19
10/15
11:37
10/15/19
11:37
General news
3-Month Bill Auction Total Amount data reported »

3-Month Bill Auction…

11:37
10/15/19
10/15
11:37
10/15/19
11:37
General news
6-Month Bill Auction Total Amount data reported »

6-Month Bill Auction…

WFC

Wells Fargo

$49.76

0.46 (0.93%)

11:36
10/15/19
10/15
11:36
10/15/19
11:36
Earnings
Wells Fargo CFO sees FY20 NII down low to mid-single-digits »

Comments provided during…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 27

    Oct

  • 29

    Oct

  • 12

    Nov

WMT

Walmart

$119.13

0.01 (0.01%)

11:36
10/15/19
10/15
11:36
10/15/19
11:36
Hot Stocks
Walmart InHome Delivery launches in Kansas City, Pittsburgh and Vero Beach »

Walmart's Bart…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 14

    Nov

ATVI

Activision Blizzard

$54.66

-0.34 (-0.62%)

, NTDOY

Nintendo

$0.00

(0.00%)

11:32
10/15/19
10/15
11:32
10/15/19
11:32
Hot Stocks
Blizzard cancels 'Overwatch' event at Nintendo store in NYC »

A previously announced…

ATVI

Activision Blizzard

$54.66

-0.34 (-0.62%)

NTDOY

Nintendo

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 07

    Nov

ENPH

Enphase Energy

$23.90

-0.85 (-3.43%)

11:25
10/15/19
10/15
11:25
10/15/19
11:25
Options
Enphase Energy call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

11:25
10/15/19
10/15
11:25
10/15/19
11:25
General news
Treasury announced a $95 B in 4- and 8-week bills for Thursday »

Treasury announced a $95…

11:25
10/15/19
10/15
11:25
10/15/19
11:25
Conference/Events
Benchmark Internet analyst to hold an analyst/industry conference call »

Internet & Digital…

MIME

Mimecast

$39.48

0.53 (1.36%)

, SPLK

Splunk

$121.10

1.43 (1.20%)

11:25
10/15/19
10/15
11:25
10/15/19
11:25
Conference/Events
FBN Securities network security/IT security to hold a luncheon meeting »

Analysts hold a group…

MIME

Mimecast

$39.48

0.53 (1.36%)

SPLK

Splunk

$121.10

1.43 (1.20%)

SAIL

SailPoint

$18.48

0.1 (0.54%)

CHKP

Check Point

$109.73

0.95 (0.87%)

PFPT

Proofpoint

$130.69

1.035 (0.80%)

ZS

Zscaler

$47.50

-0.04 (-0.08%)

FTNT

Fortinet

$79.42

0.17 (0.21%)

PANW

Palo Alto Networks

$213.94

0.29 (0.14%)

BOX

Box

$16.89

0.11 (0.66%)

FEYE

FireEye

$15.03

0.035 (0.23%)

CYBR

CyberArk

$105.00

1.87 (1.81%)

SYMC

Symantec

$23.62

0.195 (0.83%)

FSCT

ForeScout

$25.86

0.29 (1.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 24

    Oct

  • 28

    Oct

  • 29

    Oct

  • 31

    Oct

  • 06

    Nov

  • 06

    Nov

  • 06

    Nov

  • 07

    Nov

  • 07

    Nov

  • 13

    Nov

  • 19

    Nov

  • 12

    Dec

  • 16

    Dec

11:25
10/15/19
10/15
11:25
10/15/19
11:25
Conference/Events
Wolfe Research energy analysts to hold an analyst/industry luncheon »

Energy E&P Analyst…

PDFS

PDF Solutions

$13.14

0.145 (1.12%)

11:25
10/15/19
10/15
11:25
10/15/19
11:25
Conference/Events
PDF Solutions to host analyst day »

Analyst Day to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

11:25
10/15/19
10/15
11:25
10/15/19
11:25
Conference/Events
UBS leisure, gaming & lodging analyst to hold a luncheon »

Leisure, Gaming &…

AMBA

Ambarella

$55.42

2.31 (4.35%)

11:23
10/15/19
10/15
11:23
10/15/19
11:23
On The Fly
Ambarella rises after saying customers' blacklisting shouldn't hurt results »

Shares of Ambarella…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

GS

Goldman Sachs

$202.74

-3.07 (-1.49%)

, WE

We Company

$0.00

(0.00%)

11:20
10/15/19
10/15
11:20
10/15/19
11:20
Hot Stocks
Breaking Hot Stocks news story on Goldman Sachs, We Company »

Goldman Sachs says…

GS

Goldman Sachs

$202.74

-3.07 (-1.49%)

WE

We Company

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 12

    Nov

DXCM

DexCom

$150.26

-9.94 (-6.20%)

, TNDM

TNDM

11:20
10/15/19
10/15
11:20
10/15/19
11:20
Recommendations
DexCom, TNDM, Abbott analyst commentary  »

DexCom should be bought…

DXCM

DexCom

$150.26

-9.94 (-6.20%)

TNDM

TNDM

ABT

Abbott

$81.98

2.17 (2.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 04

    Nov

  • 06

    Nov

  • 13

    Nov

  • 14

    Nov

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

11:17
10/15/19
10/15
11:17
10/15/19
11:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

11:16
10/15/19
10/15
11:16
10/15/19
11:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

YUM

Yum! Brands

$112.10

-0.73 (-0.65%)

11:16
10/15/19
10/15
11:16
10/15/19
11:16
Periodicals
Taco Bell seasoned beef recalled over metal contamination concerns, CNN says »

About 2M pounds of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

  • 30

    Oct

11:15
10/15/19
10/15
11:15
10/15/19
11:15
General news
Breaking General news story  »

3-Month Bill Auction to…

11:15
10/15/19
10/15
11:15
10/15/19
11:15
General news
Breaking General news story  »

6-Month Bill Auction to…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.